använder sig av cookies för att ge dig som besökare en så bra upplevelse som möjligt.
19 November 2015

Immunovia’s new share issue subscribed to a value of SEK 305 million

The rights issue of Immunovia AB (publ) (“Immunovia” or ” the Company”) for the Company’s listing on Nasdaq First North was subscribed to SEK 305 million, which corresponds to a subscription ratio of approximately 500 percent.

The Company received SEK 60 million before issue costs and has approximately 1 100 new shareholders. Estimated first day of trading on Nasdaq First North is December 1, 2015.


Vator Securities was the exclusive financial advisor and Baker & McKenzie legal advisor to the Company in connection with the rights issue and listing on Nasdaq First North.